RxDoctor Payments Data

Erin Whalen

Nurse Practitioner · Peoria, ILNPI 1144795295

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,020 of the $34,288 with a category attached, or 81.7%. AstraZeneca accounts for 64.7% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $19,058, more than ten times the $1,507 reported in 2022. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,288in general payments, 2019–2025

Across 148 payments — averaging $231.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$22K
  • Daiichi Sankyo Inc.$10K
  • AbbVie$230
  • Novartis$223
  • Seagen Inc.$122
  • Johnson & Johnson$102
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$1,7405%
  • Speaking & faculty fees$28,02082%
  • Travel & lodging$1,0723%
  • Food & beverage$3,45610%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,288 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$1,129,044
Medicare patients
528
Services billed
71,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl32$4,838
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$1,772
Morphine Sulfate ErMorphine Sulfate23$811
Gabapentin15$448
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine25$425
Morphine Sulfate13$419
Prochlorperazine Maleate28$386
Dexamethasone38$367
Tramadol Hcl67$294
Lorazepam54$237
Oxycodone Hcl16$205
Potassium Chloride19$197
Triamcinolone Acetonide13$127
Ondansetron Hcl16$112
Levofloxacin23$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$57$2712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Peoria

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →